“It’s not a little bit more. It’s a lot more. It’s unbelievable.” —Andrew Blauvelt, MD, of Blauvelt Consulting in Annapolis, Maryland, reacting to the unprecedented response rates of atopic dermatitis treatments used in recent Chinese clinical trials compared to FDA-approved drugs.
“The food is bland, it’s poorly prepared, and it lacks the nutrients from nature that you actually need to be completely healthy.” – CMS Administrator Mehmet Oz, MD, MBA, as the agency announced the move to limit ultraprocessed foods and sugary beverages in hospitals serving Medicare and Medicaid patients.
“Although the time savings are modest… they were likely reallocating it to other patient care tasks.” – Lisa Rotenstein, MD, of the University of California San Francisco, concluded that artificial intelligence (AI) has slightly reduced the time physicians spend on electronic health records.
“We want to challenge the perception that it takes 10 to 12 years for a drug to come to market.” – FDA Commissioner Marty Macri, MD, MPH, about the agency’s initiative to streamline the drug approval process.
“The stronger the network of the old boys, the stronger the tradition of the academic medical center, the stronger the hierarchy.” – Mark Speicher, PhD, of the American Association of Colleges of Osteopathic Medicine on the systemic bias faced by osteopathic graduates during residency matching.
“Clinicians should avoid overinterpreting early signs.” —Yongzhe Li, MD, PhD, of the First Hospital of China Medical University in Shenyang, found weak evidence of some benefits of GLP-1 drugs after a comprehensive review.
“Metabolic changes appear long before cognitive decline becomes clinically apparent.” —David Vauzour, PhD, of the University of East Anglia in Norwich, England, on research identifying gut-associated blood metabolites as early biomarkers for cognitive impairment.
“The evidence base remains conflicting.” – Xiaoyan Zheng, PhD, of Southern Medical University in Guangzhou, China, said that despite its popularity, kinesiology taping lacks strong data for treating joint and muscle pain.
“I don’t want anyone to say this is a cure for long-term COVID.” – Jamie Forrest, PhD, MPH, of the University of British Columbia in Vancouver, discussing a trial where the antidepressant fluvoxamine reduced long-lasting COVID fatigue.
